UPDATE 1-Gilead's two hepatitis C drug trials meet study goals
February 04, 2013 at 14:22 PM EST
Feb 4 (Reuters) - Biotechnology company Gilead Sciences on Monday said two trials of its hepatitis C drug, the centerpiece of its oral hepatitis C treatment program, met their goals in two late-stage studies.
